CSPC Pharmaceutical Group Limited - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CSPCY Over the counter 2830 www.cspc.com.hk

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for CSPC Pharmaceutical Group Limited

Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary Endpoint - Apr 1st, 2026 8:44 am
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 and Chemotherapy as Adjuvant Treatment of Breast Cancer - Mar 23rd, 2026 7:32 pm
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Colorectal Cancer of Biparatopic HER2-targeting ADC JSKN003 - Feb 14th, 2026 5:58 am
AZN Obesity Pipeline to Get a Boost From Deal With China's CSPC - Feb 2nd, 2026 9:00 am
CSPC AstraZeneca Deal Recasts Role In Global Obesity And Diabetes Therapies - Feb 1st, 2026 8:08 am
AstraZeneca strikes deal for up to $18.5 billion to license weight-loss drugs from China's CSPC - Jan 30th, 2026 6:15 am
AstraZeneca Agrees Up to $18.5 Billion Obesity Drug Deal in China - Jan 30th, 2026 5:52 am
Trending tickers: Apple, Microsoft, Sandisk, Caterpillar and AstraZeneca - Jan 30th, 2026 2:43 am
AstraZeneca secures tie-up with Chinese firm for weight loss drugs - Jan 30th, 2026 1:18 am
AstraZeneca leans into obesity, striking wide-ranging alliance with China’s CSPC - Jan 30th, 2026 12:36 am
Is CSPC Pharmaceutical Group (SEHK:1093) Still Attractive After A 129% One-Year Share Price Surge - Jan 27th, 2026 3:07 pm
Alphamab Oncology Announces the Results of a Phase III Clinical Study of Anbenitamab (KN026) were Published in Annals of Oncology - Jan 26th, 2026 6:58 pm
Novo Nordisk and Eli Lilly Slash Obesity Drug Prices in China - Dec 30th, 2025 7:49 am
Novo Nordisk Cuts Wegovy Prices in China Ahead of Patent Expiration - Dec 29th, 2025 10:45 am
Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Breakthrough Therapy Designation by the FDA for the Treatment of PROC - Dec 19th, 2025 9:54 pm
How Regulatory Approval for CSPC Pharmaceutical’s First C5 siRNA Therapy (SEHK:1093) Has Changed Its Investment Story - Nov 7th, 2025 4:17 am
Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates - Nov 4th, 2025 5:00 am
Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for Colorectal Cancer - Oct 26th, 2025 7:51 pm
Biparatopic HER2-targeting ADC JSKN003 Was Granted Another Breakthrough Therapy Designation for HER2-Positive Advanced Colorectal Cancer - Oct 19th, 2025 11:21 pm
Research Updates on a Phase III Clinical Trial of Anbenitamab (KN026) Presented at ESMO Congress 2025 LBA Oral Presentation Session - Oct 18th, 2025 12:59 am